Cohance Lifesciences to invest $18 million in NJ Bio, Aruka Bio
In short
Cohance Lifesciences said it will put $18 million into NJ Bio and Aruka Bio. The reporting says this is meant to strengthen its work on antibody-drug conjugates, or ADCs.
The company wants to join research, manufacturing and customer services more closely. It was not stated exactly how much control it will take or when the deals will close.
What the reporting says
Cohance Lifesciences said it will invest $18 million in NJ Bio and Aruka Bio to sharpen its focus on antibody-drug conjugates, according to the reporting. The summaries say the money will support deeper integration of NJ Bio’s customer-facing services and development of Aruka Bio’s proprietary pipeline, with the deals funded through internal accruals. The exact ownership changes and closing timeline were not stated.
Why it matters
Cohance Lifesciences is reported to be investing $18 million across NJ Bio and Aruka Bio as part of a broader ADC strategy. The summaries say the move would deepen customer-facing services, support Aruka’s pipeline, and expand Cohance’s end-to-end CRDMO offering. The reporting indicates internal accruals will fund the transactions, but it does not give the final stake percentages or completion date.